Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR | Market Cap | 102.48B +74.2% |
| Revenue (ttm) | 48.59B +6.4% |
| Net Income | 5.56B -84.5% |
| EPS | 60.34 -84.5% |
| Shares Out | 92.17M |
| PE Ratio | 18.43 |
| Forward PE | 16.35 |
| Dividend | 5.00 (0.45%) |
| Ex-Dividend Date | Jul 22, 2025 |
| Volume | 189,062 |
| Open | 1,111.80 |
| Previous Close | 1,111.80 |
| Day's Range | 1,086.40 - 1,136.30 |
| 52-Week Range | 768.65 - 1,231.00 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 1,264.50 (+15.57%) |
| Earnings Date | May 18, 2026 |
About Strides Pharma Science
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under th... [Read more]
Financial Performance
In fiscal year 2026, Strides Pharma Science's revenue was 48.59 billion, an increase of 6.43% compared to the previous year's 45.65 billion. Earnings were 5.56 billion, a decrease of -84.52%.
Financial StatementsNews
Strides Pharma Science Transcript: Q4 25/26
FY 2026 saw record EBITDA and PAT, driven by ex-U.S. market growth and margin expansion. U.S. business faced headwinds from a weak flu season and competition, but new launches and controlled substances are expected to drive growth from H2 FY 2027.
Strides Pharma Science Quarterly report: Q4 2026
Strides Pharma Science has published its Q4 2026 quarterly earnings report on May 18, 2026.
Strides Pharma Science Slides: Q4 2026
Strides Pharma Science has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 18, 2026.
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Strides Pharma shares over 3% after acquiring generic brands from Sandoz for US$ 12 million
Strides Pharma Science shares gained over 3% after the company announced a strategic acquisition aimed at expanding its footprint in the Sub-Saharan Africa (SSA) region. As of 9:38 AM, the…
Strides Pharma Science acquires generic brands from Sandoz for US$ 12 million
Strides Pharma Science Limited has announced a strategic acquisition to bolster its presence in the Sub-Saharan Africa (SSA) region. The company, through its step-down subsidiary Strides Pharma Intern...
Strides Pharma Science Transcript: Q3 25/26
Gross margins and profitability improved, with EBITDA and PAT showing strong year-on-year growth. Ex-U.S. markets drove revenue expansion, while U.S. business remained flat due to seasonal and competitive factors. Balance sheet metrics and operational cash flow strengthened.
Strides Pharma Science Quarterly report: Q3 2026
Strides Pharma Science has published its Q3 2026 quarterly earnings report on January 30, 2026.
Strides Pharma Science Slides: Q3 2026
Strides Pharma Science has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 30, 2026.
Strides Pharma Science shares jump over 4% after Q3 profit surges 130% YoY to Rs 202 crore
Shares of Strides Pharma Science climbed more than 4% on the NSE on Thursday, reacting positively to the company’s strong...
Strides Pharma Q3 Results: Net profit surges 130% YoY to Rs 202 crore, revenue up 3.6%
Strides Pharma Science reported a strong set of financial results for the third quarter, delivering sharp growth in profitability and...
Strides Pharma Science Transcript: Q2 25/26
Q2 and H1 FY26 delivered strong growth in revenue, margins, and profitability, driven by disciplined execution, operating leverage, and a focus on sustainable, long-term growth. U.S. and other regulated markets showed steady performance, with robust cash flow and debt reduction.
Strides Pharma Science Quarterly report: Q2 2026
Strides Pharma Science has published its Q2 2026 quarterly earnings report on October 31, 2025.
Strides Pharma Science Slides: Q2 2026
Strides Pharma Science has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 31, 2025.
Strides Pharma Science Transcript: Q1 25/26
Strong quarterly results with revenue of INR 11.2 billion, 19.5% EBITDA margin, and 81% EPS growth year-on-year. U.S. and growth markets performed well, while access markets faced funding challenges. Long-term U.S. sales guidance of $400 million by FY2028 remains intact.
Strides Pharma Science Quarterly report: Q1 2026
Strides Pharma Science has published its Q1 2026 quarterly earnings report on July 29, 2025.
Strides Pharma Science Slides: Q1 2026
Strides Pharma Science has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 29, 2025.
Strides Pharma shares hit 52-week high, jumps 3% after Q1 PAT jumps 81% YoY
Shares of Strides Pharma Science Ltd surged over 3% on July 29, hitting a fresh 52-week high of ₹968 on the NSE after the company reported robust Q1FY26 earnings. The stock was last seen trading at ₹9...
Strides Pharma Q1 Results: Revenue rises 6.2% YoY to Rs 1119 crore, Net Profit at Rs 105.6 crore
Strides Pharma Science Ltd reported a strong performance for the quarter ended June 30, 2025, with revenue from operations rising 6.2% YoY to ₹1119.7 crore. The company’s operational profit after tax ...
Strides Pharma Science Transcript: Q4 24/25
FY25 saw robust revenue and EBITDA growth, with US business outperforming and margins expanding. Debt reduction, strong cash flow, and increased R&D investment position the company for continued growth, with a focus on high-value US launches and stable margins.
Strides Pharma Science Annual report: Q4 2025
Strides Pharma Science has published its Q4 2025 annual report on May 22, 2025.
Strides Pharma Science Quarterly report: Q4 2025
Strides Pharma Science has published its Q4 2025 quarterly earnings report on May 22, 2025.
Strides Pharma receives USFDA approval for Celecoxib Capsules
Strides Pharma Science Limited announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has received approval from the United States Food & Drug Adm...
Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation
Strides Pharma Science Limited has announced the incorporation of a new step-down wholly owned subsidiary named Pivot Path Private Limited through its subsidiary Arco Lab Private Limited. The new enti...
Strides Pharma Science Transcript: Q3 24/25
Strong Q3 and nine-month results driven by robust US and growth/access markets, margin expansion, and successful soft-gelatin business demerger. Guidance for FY25 and FY28 remains on track, with focus on debt reduction, R&D, and new product launches.